HK1093223A1 - Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage - Google Patents

Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage

Info

Publication number
HK1093223A1
HK1093223A1 HK06114003.0A HK06114003A HK1093223A1 HK 1093223 A1 HK1093223 A1 HK 1093223A1 HK 06114003 A HK06114003 A HK 06114003A HK 1093223 A1 HK1093223 A1 HK 1093223A1
Authority
HK
Hong Kong
Prior art keywords
single nucleotide
vitamin
correlation
compositions
methods
Prior art date
Application number
HK06114003.0A
Other languages
English (en)
Chinese (zh)
Inventor
Darrel W Stafford
Tao Li
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34393028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1093223(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of HK1093223A1 publication Critical patent/HK1093223A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HK06114003.0A 2003-09-23 2006-12-20 Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage HK1093223A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50552703P 2003-09-23 2003-09-23
PCT/US2004/031481 WO2005030039A2 (en) 2003-09-23 2004-09-23 Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage

Publications (1)

Publication Number Publication Date
HK1093223A1 true HK1093223A1 (en) 2007-02-23

Family

ID=34393028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06114003.0A HK1093223A1 (en) 2003-09-23 2006-12-20 Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage

Country Status (13)

Country Link
US (6) US7687233B2 (xx)
EP (4) EP1842920B2 (xx)
JP (4) JP2007506433A (xx)
AT (1) ATE455174T1 (xx)
AU (2) AU2004275828B2 (xx)
CA (1) CA2539434C (xx)
DE (1) DE602004025157D1 (xx)
DK (2) DK2380985T3 (xx)
ES (2) ES2453895T3 (xx)
HK (1) HK1093223A1 (xx)
PL (1) PL1842920T5 (xx)
PT (1) PT2380985E (xx)
WO (1) WO2005030039A2 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004025157D1 (de) * 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
ES2344413T3 (es) * 2003-10-14 2010-08-26 Baxter International Inc. Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados.
EP1781779A2 (en) * 2004-08-02 2007-05-09 Novozymes A/S Creation of diversity in polypeptides
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
EP1809767B1 (en) * 2004-10-18 2011-09-07 University of Washington Methods and compositions for predicting response to warfarin
EP1831402B1 (en) * 2004-12-21 2010-06-09 Academia Sinica Genetic variants of vkorc1 predicting warfarin sensitivity
EP2295547B1 (en) * 2005-02-28 2017-09-20 Baxalta GmbH Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependant protein expression
US20090325226A1 (en) * 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
MX2007012704A (es) 2005-04-13 2008-01-14 Astrazeneca Ab Celula huesped que comprende vector para la produccion de proteinas que requieren carboxilacion-gamma.
US8500720B2 (en) * 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
WO2007075976A2 (en) * 2005-12-21 2007-07-05 Inspiration Biopharmaceuticals, Inc. Method of producing biologically active vitamin k dependent proteins by recombinant methods
US20070298426A1 (en) * 2006-06-02 2007-12-27 Academia Sinica Warfarin dosage prediction
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
UA101497C2 (ru) 2008-04-24 2013-04-10 Селтик Фарма Пег Лтд. Конъюгаты фактора ix с увеличенным временем полужизни
US20110243958A1 (en) * 2008-10-15 2011-10-06 President And Fellows Of Harvard College Antimicrobial agents that target bacterial vkor
WO2011003153A1 (en) 2009-07-10 2011-01-13 Csl Limited Method of increasing the expression yield of vitamin k-dependent proteins
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
JP2012139232A (ja) * 2012-03-15 2012-07-26 Univ Of North Carolina At Chapel Hill 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
JP2014221048A (ja) * 2014-06-16 2014-11-27 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
BR102015012334A2 (pt) * 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
AU5864086A (en) 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0289586A4 (en) 1986-11-17 1990-04-10 New England Medical Ct INCREASING GAMMA CARBOXYLATION OF RECOMBINANT, VITAMIN K-DEPENDENT PROTEINS.
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
WO1991001372A1 (en) 1989-07-17 1991-02-07 New England Medical Center Hospitals, Inc. VITAMIN K-DEPENDENT η-CARBOXYLASE
JPH05508551A (ja) * 1990-07-23 1993-12-02 ザイモジェネティクス，インコーポレイティド ガンマーカルボキシラーゼおよび使用の方法
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
DK0574402T3 (da) 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5698765A (en) * 1991-12-02 1997-12-16 The Ontario Cancer Institute Mouse having a disrupted CD4 gene
WO1993018144A1 (en) * 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5625122A (en) * 1992-04-24 1997-04-29 The Ontario Cancer Institute Mouse having a disrupted lck gene
JP3741447B2 (ja) * 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−１遺伝子の機能が欠損したマウス
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5547835A (en) * 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
GB2303853B (en) 1994-06-16 1998-12-23 Us Health Variant alleles in cytochrome P450 expressing enzymes involved in metabolic processes
ZA965853B (en) * 1995-07-13 1998-01-12 Du Pont Merck Pharma Asymmetric synthesis of r and s warfarin and its analogs.
DE19625049A1 (de) 1996-06-22 1998-01-02 Inst Pflanzengenetik & Kultur Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält
WO2002102994A2 (en) * 2001-03-21 2002-12-27 Human Genome Sciences, Inc. Human secreted proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
EP1042473A1 (en) * 1997-12-24 2000-10-11 Immunex Corporation V201 dna and polypeptides
US5896337A (en) 1998-02-23 1999-04-20 Micron Technology, Inc. Circuits and methods for multi-level data through a single input/ouput pin
WO2000003015A2 (en) * 1998-07-10 2000-01-20 Incyte Pharmaceuticals, Inc. Human transport protein homologs
CN1289448A (zh) * 1998-11-18 2001-03-28 皇家菲利浦电子有限公司 荧光材料
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6453244B1 (en) * 2000-02-10 2002-09-17 Stanford University Detection of polymorphisms by denaturing high-performance liquid chromatography
US6492115B1 (en) * 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
KR100880624B1 (ko) 2000-10-02 2009-01-30 노보 노르디스크 헬스 케어 악티엔게젤샤프트 비타민 ｋ-의존 단백질의 생산 방법
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
DE602004025157D1 (de) * 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
ES2344413T3 (es) 2003-10-14 2010-08-26 Baxter International Inc. Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados.
EP1809767B1 (en) 2004-10-18 2011-09-07 University of Washington Methods and compositions for predicting response to warfarin
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
WO2006067116A1 (en) 2004-12-21 2006-06-29 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
EP1831402B1 (en) * 2004-12-21 2010-06-09 Academia Sinica Genetic variants of vkorc1 predicting warfarin sensitivity
EP2295547B1 (en) 2005-02-28 2017-09-20 Baxalta GmbH Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependant protein expression
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
MX2007012704A (es) 2005-04-13 2008-01-14 Astrazeneca Ab Celula huesped que comprende vector para la produccion de proteinas que requieren carboxilacion-gamma.
ATE486128T1 (de) 2005-12-02 2010-11-15 Univ Wake Forest Health Sciences Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
WO2007075976A2 (en) 2005-12-21 2007-07-05 Inspiration Biopharmaceuticals, Inc. Method of producing biologically active vitamin k dependent proteins by recombinant methods
US20070298426A1 (en) 2006-06-02 2007-12-27 Academia Sinica Warfarin dosage prediction
JP2009005240A (ja) * 2007-06-25 2009-01-08 Nec Tokin Corp 無線ネットワークシステムおよび無線ネットワーク通信方法

Also Published As

Publication number Publication date
JP2010268803A (ja) 2010-12-02
AU2004275828B2 (en) 2010-04-29
ES2453895T3 (es) 2014-04-08
EP1842920A1 (en) 2007-10-10
AU2010203318A1 (en) 2010-08-12
ES2339710T5 (es) 2017-10-05
US20110124000A1 (en) 2011-05-26
US7524665B2 (en) 2009-04-28
US20060240440A1 (en) 2006-10-26
US20090215045A1 (en) 2009-08-27
US7482141B2 (en) 2009-01-27
EP1670947A2 (en) 2006-06-21
EP2380985B1 (en) 2014-01-01
EP1670947B1 (en) 2015-04-01
US7858318B2 (en) 2010-12-28
JP2007506433A (ja) 2007-03-22
PL1842920T3 (pl) 2010-06-30
AU2010203318B2 (en) 2012-07-12
JP2012161315A (ja) 2012-08-30
EP1842920B2 (en) 2017-06-21
EP1670947A4 (en) 2008-11-05
US8426128B2 (en) 2013-04-23
ES2339710T3 (es) 2010-05-24
CA2539434C (en) 2014-03-18
US7687233B2 (en) 2010-03-30
PL1842920T5 (pl) 2018-04-30
EP2336360A1 (en) 2011-06-22
DK1842920T3 (da) 2010-05-03
US20070009950A1 (en) 2007-01-11
DK1842920T4 (da) 2017-08-21
DK2380985T3 (en) 2014-03-17
US20090215061A1 (en) 2009-08-27
WO2005030039A3 (en) 2005-07-21
ATE455174T1 (de) 2010-01-15
EP2380985A1 (en) 2011-10-26
US8097410B2 (en) 2012-01-17
US20070190614A1 (en) 2007-08-16
EP1842920B1 (en) 2010-01-13
DE602004025157D1 (de) 2010-03-04
PT2380985E (pt) 2014-03-26
JP5840539B2 (ja) 2016-01-06
JP2015180205A (ja) 2015-10-15
AU2004275828A1 (en) 2005-04-07
CA2539434A1 (en) 2005-04-07
WO2005030039A2 (en) 2005-04-07
JP5094920B2 (ja) 2012-12-12

Similar Documents

Publication Publication Date Title
HK1093223A1 (en) Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage
WO2006057918A3 (en) Detection of nucleic acid variation by cleavage-amplification method
WO2007066831A3 (en) Method of detecting human papilloma virus by using nucleic acid amplification method and nucleic acid chain-immobilized carrier
WO2004013357A3 (en) Nucleotide sequences specific to francisella tularensis and methods for the detection of francisella tularensis
HK1098792A1 (en) Base specific cleavage of methylation-specific amplification products in combination with mass analysis
ATE330038T1 (de) Nukleinsäure-biosensor
WO2008034110A3 (en) Use of taq polymerase mutant enzymes for dna amplification in the presence of pcr inhibitors
AU2003241311A1 (en) Simple catalytic dna biosensors for ions based on color changes
EP1943353A4 (en) HEALTH CONDITION TEST
WO2005073722A3 (en) Luminogenic and nonluminogenic multiplex assay
WO2003087390A3 (en) Methods for detecting abnormally methylated nucleic acid in heterogeneous biological samples
WO2003054166A3 (en) Nucleotide polymorphisms associated with osteoarthritis
EP1741793A4 (en) HYBRIDIZATION PROCESS
WO2007067557A3 (en) Methods for cyclic nucleotide determination
WO2005026389A3 (en) Ligation-based method of analysis of single nucleotide polymorphisms on genomic dna
WO2004009843A3 (de) Nachweis von mikroorganismen
WO2004099755A3 (en) Method of electrochemical detection of somatic cell mutations
WO2006065971A3 (en) Compositions and methods for polynucleotide amplification and detection
WO2002077285A3 (en) Methods of determining the presence of polynucleotides employing amplification
WO2002079512A3 (en) Method for detection and quantification of the fungus aspergillus fumigatus using quantitative pcr
EP1650300A4 (en) METHOD FOR ASSESSING THE RISK OF DRUG-INDUCED GRANULOCYTOPENIA
WO2002079513A3 (en) Method for the detection and quantification of the fungus stachybotrys chartarum using quantitative pcr
WO2005003388A3 (en) Fluorescence assays for nucleic acid polymerase activity
WO2004022784A3 (en) Strand specific detection and quantification
WO2006023768A3 (en) Methods and materials for detecting mutations in quasispecies having length polymorphism

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200921